She completed a residency in internal medicine at Holy Family Hospital, Catholic University of Korea.

Lee is a participating member in the Gynecologic Oncology Group, American Association for Cancer Research, American Society for Clinical Oncology, and the Breast and Gynecologic Malignancies Faculty of the NCI Center for Cancer Research (CCR).

She is the principal investigator of ongoing phase 1 and 2 studies, with a PARP inhibitor (olaparib) in combination with carboplatin or cediranib, and other biologic agents.

Her research has expanded to include the use of CRISPR-Cas9 mediated therapeutic editing of genes involved in disease causing such as PARP1, Rpe65 and Mct8.

[4][5] Additionally, Lee has published clinical guidelines for the management of acromegaly, adrenal incidenteloma, and atrial fibrillation.